Ministry of Health & Family Welfare
(Central TB Division)

Meeting Notice

Dear Manufacturer,

As you are aware that the National Tuberculosis Elimination Programme (NTEP) of the Ministry of Health and Family Welfare of the Government of India is continuing its efforts in combating the Tuberculosis by effective prevention, control and cure of this disease in pursuant of the pledge by the Hon'ble Prime Minister of India to completely eliminate TB by 2025. Your continuous participation in providing the TB medicines to treat this disease is a valuable and complementary part of these efforts.

To ensure the patient compliance especially for the patients in Paediatric age group, the programme is planning to procure Child Friendly formulations like Scored Dispersible Tablet, Dispersible Tablet, Syrup, Scored tablet, Capsules, film-coated tablet or Gel capsules etc. for the drug use to manage the drug resistant TB (Levofloxacin, Moxifloxacin, Ethionamide, Pyrazinamide, Ethambutol, Isoniazid, Linezolid, Clofazimine, Rifampicin, Amoxicillin-Clavulanate and supplementary drugs Pyridoxine – 10 mg, PAS etc.) The Programme is interested to explore the available formulations of these drugs with Indian manufacturers. These drugs, as per the treatment guidelines of the programme, is an essential constituent of the pediatric treatment regimen. Therefore, the procurement of these drugs is necessary.

The objective is the meeting is-

1. **To have the information of availability of child friendly DR TB formulations and future scale up of production of these anti TB drugs (List enclosed).**
2. **To have the information of availability of Ethambutol 100 child friendly formulations and future scale up of production of these anti TB drugs.**
3. **To have the information of availability of INH 100 child friendly formulation and future scale up of production of these anti TB drugs.**
4. **To have the information of availability of pyridoxine10 mg, 50mg & 100mg and future scale up of production of these anti TB drugs.**
5. **To have the information of availability of Co-trimaxozole and future scale up of production of these anti TB drugs.**

Child Friendly medicine in order of preference- Scored Dispersible Tablets → Dispersible Tablets → Syrup → Scored tablet →Capsules → film-coated tablet/Gel capsules

In order to facilitate a dialogue in this direction, you are requested to please join the meeting via Video Conference(VC) which has been organized and scheduled by DDG(TB), Central TB Division, Ministry of Health & Family Welfare (MoHFW), Govt. of India, on 16th June, 2020 at 11.00am. The detail to join the VC (on Google Meet) is given below:

To join the video meeting, click this link: https://meet.google.com/nfj-guwm-ger

A line of confirmation to attend this meeting shall be highly appreciated. Please send the confirmation to ctddelhi@rntcp.org, drugs@rntcp.org. The meeting agenda is enclosed herewith as Annexure-I.

Annexure 1: Agenda for meeting

Meeting to discuss on Child friendly formulations for DRTB treatment

Meeting Agenda

Date & Time: 16.06.2020(Tuesday), 11.00 – 12.00 Noon

Agenda points

1. Availability and future scale up of production plan for Child friendly formulations for DRTB treatment
2. Availability of following Child Friendly formulations:

Detail of Child Friendly formulations for Drug Resistant TB patients under NTEP									
Sl. No.	**Drug Name**	**Manufacturer name**	**Availability of anti TB drug in the form of**						
			Scored Dispersible Tablet	**Dispersible Tablet**	**Syrup**	**Scored tablet**	**Capsules**	**Film-coated tablet**	**Gel capsules**
			(Strength)	**(Strength)**	**(Strength)**	**(Strength)**	**(Strength)**	**(Strength)**	**(Strength)**
1	Clofazimine	M/s……	50mg	100mg	….	…	….	….	….
2	Cycloserine								
3	Ethionamide								
4	Levofloxacin								
5	Moxifloxacin								
6	Linezolid								
7	Ethambutol								
8	Isoniazid								
9	Pyrazinamide								
10	Rifampicin								
11	Pyridoxine								
12	Na-PAS								
13	Kanamycin								
14	Amikacin								
15	Meropenem								
16	Amoxicillin clavulanic								
17	Imipenem/ cilastatin								